Key2Compliance celebrates announcement from Atrogi

Key2Compliance celebrates that Atrogi has received approval from the German authority BfArM to initiate a phase 1 study with their small molecule drug candidate ATR-258 in healthy volunteers and Type 2 Diabetics.

Atrogi is one of Key2Complience clients and an early-stage Swedish pharma company developing a novel solution for the treatment of Type 2 Diabetes. The trial is expected to be completed by year end 2022 with the final report in Q1/2,2023.

Johanna Fondell, senior consultant at Key2Compliance, has played an important role in the project as clinical project manager supporting the Atrogi team selecting the CRO and preparing the submission package for BfArM. “I have enjoyed being part of such an important project and the great teamwork” says Johanna.

Press release from Atrogi:
“Atrogi receives regulatory approval from German health authority BfArM to initiate phase 1 study of ATR-258 in type 2 diabetes”

About Atrogi
Atrogi, a Swedish pharmaceutical R&D company, develops a revolutionizing solution for the treatment of type 2 diabetes aimed at the global market. Atrogi was founded in 2013 based on results from professor Tore Bengtsson. Please visit: www.atrogi.com